Literature DB >> 32385092

3,4-Methylenedioxypyrovalerone: Neuropharmacological Impact of a Designer Stimulant of Abuse on Monoamine Transporters.

Charlotte P Magee1, Christopher L German1, Yasmeen H Siripathane1, Peter S Curtis1, David J Anderson1, Diana G Wilkins1, Glen R Hanson1, Annette E Fleckenstein2.   

Abstract

Methylenedioxypyrovalerone (MDPV) is an abused synthetic cathinone, commonly referred to as a "bath salt." Because the dopamine (DA) transporter (DAT) and vesicular monoamine transporter-2 (VMAT-2) are key regulators of both the abuse and neurotoxic potential of structurally and behaviorally related agents, the impact of MDPV on these transporters was investigated. Results revealed that a single in vivo MDPV administration rapidly (within 1 hour) and reversibly increased both rat striatal DAT and VMAT-2 activity, as assessed via [3H]DA uptake in synaptosomes and synaptic vesicles, respectively, prepared from treated rats. There was no evidence of an MDPV-induced increase in plasmalemmal membrane DAT surface expression. Plasma concentrations of MDPV increased dose-dependently as assessed 1 hour after 2.5 and 5.0 mg/kg (s.c.) administration and returned to levels less than 10 ng/ml by 18 hours after 2.5 mg/kg (s.c.). Neither pretreatment with a D1 receptor (SCH23390), a D2 receptor (eticlopride), nor a nicotinic receptor (mecamylamine) antagonist attenuated the MDPV-induced increase in DAT activity. In contrast, eticlopride pretreatment attenuated both the MDPV-induced increase in VMAT-2-mediated DA uptake and an associated increase in cytoplasmic-associated vesicle VMAT-2 immunoreactivity. SCH23390 did not attenuate the MDPV-induced increase in VMAT-2 activity. Repeated MDPV injections did not cause persistent DAergic deficits, as assessed 7 to 8 days later. The impact of MDPV on striatal and hippocampal serotonergic assessments was minimal. Taken together, these data contribute to a growing pharmacological rubric for evaluating the ever-growing list of designer cathinone-related stimulants. The profile of MDPV compared with related psychostimulants is discussed. SIGNIFICANCE STATEMENT: Pharmacological characterization of the synthetic cathinone, 3,4-methylenedioxypyrovalerone (MDPV; commonly referred to as a "bath salt"), is critical for understanding the abuse liability and neurotoxic potential of this and related agents. Accordingly, the impact of MDPV on monoaminergic neurons is described and compared with that of related psychostimulants.
Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32385092      PMCID: PMC7366288          DOI: 10.1124/jpet.119.264895

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  45 in total

1.  Reinforcing and neurochemical effects of the "bath salts" constituents 3,4-methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxy-N-methylcathinone (methylone) in male rats.

Authors:  Charles W Schindler; Eric B Thorndike; Steven R Goldberg; Kurt R Lehner; Nicholas V Cozzi; Simon D Brandt; Michael H Baumann
Journal:  Psychopharmacology (Berl)       Date:  2015-08-29       Impact factor: 4.530

2.  Bupropion increases striatal vesicular monoamine transport.

Authors:  Kristi S Rau; Elisabeth Birdsall; Jarom E Hanson; Kamisha L Johnson-Davis; F Ivy Carroll; Diana G Wilkins; James W Gibb; Glen R Hanson; Annette E Fleckenstein
Journal:  Neuropharmacology       Date:  2005-07-07       Impact factor: 5.250

3.  3,4-Methylenedioxypyrovalerone prevents while methylone enhances methamphetamine-induced damage to dopamine nerve endings: β-ketoamphetamine modulation of neurotoxicity by the dopamine transporter.

Authors:  John H Anneken; Mariana Angoa-Pérez; Donald M Kuhn
Journal:  J Neurochem       Date:  2015-03-02       Impact factor: 5.372

4.  Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein.

Authors:  Jannine G Truong; Amy H Newman; Glen R Hanson; Annette E Fleckenstein
Journal:  Eur J Pharmacol       Date:  2004-11-03       Impact factor: 4.432

5.  Functional connectivity, behavioral and dopaminergic alterations 24 hours following acute exposure to synthetic bath salt drug methylenedioxypyrovalerone.

Authors:  Luis M Colon-Perez; Jose A Pino; Kaustuv Saha; Marjory Pompilus; Sherman Kaplitz; Nafisa Choudhury; Darin A Jagnarine; Jean R Geste; Brandon A Levin; Isaac Wilks; Barry Setlow; Adriaan W Bruijnzeel; Habibeh Khoshbouei; Gonzalo E Torres; Marcelo Febo
Journal:  Neuropharmacology       Date:  2018-05-03       Impact factor: 5.250

6.  Mechanisms underlying methamphetamine-induced dopamine transporter complex formation.

Authors:  Gregory C Hadlock; Anthony J Baucum; Jill L King; Kristen A Horner; Glen A Cook; James W Gibb; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2009-01-13       Impact factor: 4.030

7.  Methamphetamine self-administration and the effect of contingency on monoamine and metabolite tissue levels in the rat.

Authors:  Katharine A Brennan; Joyce Colussi-Mas; Caleb Carati; Rod A Lea; Paul S Fitzmaurice; Susan Schenk
Journal:  Brain Res       Date:  2009-12-03       Impact factor: 3.252

8.  Cocaine alters vesicular dopamine sequestration and potassium-stimulated dopamine release: the role of D2 receptor activation.

Authors:  Sarah J Farnsworth; Trent J Volz; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2008-11-26       Impact factor: 4.030

9.  Self-administration of the synthetic cathinone MDPV enhances reward function via a nicotinic receptor dependent mechanism.

Authors:  Jean R Geste; Marjory Pompilus; Marcelo Febo; Adriaan W Bruijnzeel
Journal:  Neuropharmacology       Date:  2018-05-09       Impact factor: 5.250

10.  Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter.

Authors:  Krasnodara N Cameron; Renata Kolanos; Ernesto Solis; Richard A Glennon; Louis J De Felice
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

View more
  2 in total

1.  Human Neuronal Cell Lines as An In Vitro Toxicological Tool for the Evaluation of Novel Psychoactive Substances.

Authors:  Valeria Sogos; Paola Caria; Clara Porcedda; Rafaela Mostallino; Franca Piras; Cristina Miliano; Maria Antonietta De Luca; M Paola Castelli
Journal:  Int J Mol Sci       Date:  2021-06-24       Impact factor: 5.923

2.  Acute MDPV Binge Paradigm on Mice Emotional Behavior and Glial Signature.

Authors:  Mafalda Campeão; Luciana Fernandes; Inês R Pita; Cristina Lemos; Syed F Ali; Félix Carvalho; Paulo Rodrigues-Santos; Carlos A Fontes-Ribeiro; Edna Soares; Sofia D Viana; Frederico C Pereira
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.